Skip to main content.

AATRU Clinical Trials

Our clinical trials are funded by the NIH and Pharma and focus on understanding the origins of asthma, how we can decrease asthma morbidity and mortality using translational methods and development and testing of new biologics for precision based individualized medicine.

group of masked researchers making a heart shape with their handsIn 2020, we expanded our research unit in response to the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leading to the COVID-19 pandemic to evaluate prevention and treatment of this infection. We currently have >25 ongoing studies, all of which have opportunities for enrollment, research and collaboration.

Interested in Enrolling in a Clinical Study?

complete the clinical study interest form

Information on current studies may be found by choosing a title below:

Federally Funded Studies


Improving Medication Adherence with Telehealthcare Medication Therapy Management to Change Health Outcomes in Adolescents and Young Adults with Asthma.


A multi-center, randomized, 48-month, parallel- group, non-inferiority, phase III study to compare the effectiveness of 500 mcg QD or alternate regimen of roflumilast (Daliresp) therapy versus 250 mg QD, 500 mg QD three times per week, or alternate regimen of azithromycin therapy to prevent COPD exacerbations.

More Information

Lung Health Cohort (LHC)

The ALA-LHC is a longitudinal, multi-center cohort study that will enroll approximately 4,000 young adults between the ages of 25-35 who do not have severe lung disease. The overarching objective of the ALA-LHC is to establish a national cohort of young adults for the purpose of defining lung health and developing targets to intercept chronic lung disease at its earliest stages.

More Information


PrecISE is an NHLBI-sponsored network established to conduct a phase 2 proof-of-concept study to test interventions in biomarker-defined subgroups of patients with severe asthma.

More Information


The mission of the SARP is to improve the understanding of severe asthma through integrated study of its clinical and biological features and to evaluate their changes over time. The ultimate goal of these efforts is to promote better treatments for severe asthma.

More Information

Pharmaceutical Studies


A Phase 4, Multicenter, Randomized, Double-blind, Parallel Group, Placebo controlled Study to Evaluate the Effect of Benralizumab on Structural and Lung Function Changes in Severe Eosinophilic Asthmatics.

More Information


A Phase III, Multicentre, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of MEDI3506 in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations.

More information


A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils.

More Information


A randomized, double-blind, placebo-controlled, parallel group study to evaluate the effect of Dupilumab on exercise capacity in patients with moderate-to-severe asthma.

More Information


Randomized, double blind, placebo-controlled study to evaluate the effect of dupilumab on airway inflammation through assessments of lung function, mucus plugging and other lung imaging parameters in patients with asthma.

More information


A Clinical Evaluation of the RheOx Bronchial Rheoplasty System for the Treatment of the Symptoms of Chronic Bronchitis in Adult Patients with COPD.

More information


A randomized, double-blind, placebo-controlled, parallel-group, dose ranging study to assess the efficacy, safety, and tolerability of subcutaneous amlitelimab in adult participants with moderate-to-severe asthma.


Mechanistic study of the effect of itepekimab on airway inflammation in patients with COPD.

Investigator Initiated Studies

AATRU Biobank

Translational Studies

Dupilumab IIS

Completed Studies
  • TEVA
  • Theravance
  • Shinogi Cough
  • Regeneron R668-AS-1903
  • Vestige
hand holding a mobile device

Interested in Enrolling in a Clinical Study?

Complete the clinical study interest form and you will be contacted within 3 business days.
Clinical Study Interest Form
Internal Medicine

University of Kansas Medical Center
Internal Medicine
Pulmonary, Critical Care, and Sleep Medicine Division
Mailstop 3007
3901 Rainbow Boulevard
Kansas City, KS 66160
Phone: 913-588-6045